Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Double Wood Supplements is a U.S.-based consumer health company that develops and sells science-backed, primarily single-ingredient dietary supplements through a direct-to-consumer e-commerce model. Founded in 2013 by twin brothers Reese Wood and Evan Wood, the company emphasizes transparency, third-party testing, certificates of analysis, and practitioner-grade positioning for a broad portfolio spanning brain health, sleep, healthy aging, immune support, liver health, metabolism, and other wellness categories. Its products are marketed as nutritional supplements rather than prescription therapeutics, so the business does not operate a traditional drug-development pipeline. Double Wood manufactures in a cGMP facility in the United States using global ingredients and has expanded internationally. The company was acquired by Boyne Capital in late 2020/announced January 2021 and was subsequently sold to Gryphon Investors in January 2026.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Double Wood Supplements.